MME and Optimar Announce Merger

OXFORD, MS, and MONTCLAIR, NJ, October 2, 2006 — Medical Marketing Economics, LLC (MME) and Optimar Strategic Consulting, LLC (Optimar) announce their merger effective October 1, 2006.  MME is the global leader in the development of value-based pricing strategies and research for health care goods and services.  Optimar has become a premier consultancy in the field of pharmaceutical pricing, contracting, and the development of managed care strategies by applying a unique combination of manufacturer and client perspectives.  In joining their strengths, MME and Optimar have created a new MME capable of developing and delivering the most comprehensive pricing strategies including market-focused research, actionable tactics, and implementation support for our clients.  Our activities will continue to be value-based, but the focus will broaden to include all actions that optimize marketing in the dynamic health care environment.

MME, founded in 2000 by E.M. (Mick) Kolassa, PhD, and his partners, provides clients with comprehensive strategic guidance in the development of pricing and competitive strategies and the execution of customized marketing research for the global pharmaceutical industry.  Optimar was founded in 2002 by Jack Mycka and W. Paul DeBree and applies its ValueFrameSM methodology from both the manufacturer perspective and the customer perspective to build strategies and tactics that work both in theory and in practice.   

From offices in Montclair, New Jersey, and Oxford, Mississippi, MME’s seven partners and their associates will provide unparalleled strategic and tactical support to pharmaceutical and biotech-related clients for pricing strategies and tactics.  The new MME offers pharmaceutical, biotech, medical device, and health care related clients comprehensive guidance and services in the areas of:

  1. Development of pricing strategies and associated tactics, facilitated by the use of our Pricing Strategy AssessmentSM and ValueFrameSM methodology
  2. Design and implementation of contracting (i.e., tactical pricing) with existing and emerging customer segments
  3. Quantitative and qualitative pricing research with providers, payers, and patients in the US and European markets designed to provide market-wide knowledge
  4. Custom studies that encompass segmentation, positioning, target product profile development, and product tracking
  5. Strategic guidance in the assessment and development of competitive strategies through our proprietary Competitive Engagement  Simulation®
  6. Research and market understanding from multiple customers’ points of view to provide Total Marketspace AwarenessSM  
  7. Infrastructure evaluation, planning, and development
  8. Training and education in all of these areas
  9. Expert testimony and litigation support in pharmaceutical marketing and pricing issues.

For more information, please visit www.m2econ.com or e-mail us at info@m2econ.com.

The new MME is ready to help you learn from our experience and profit from our thinking.SM